Onemednet Corporation has selected Inka Health, a subsidiary of Onco-Innovations Limited, to spearhead a groundbreaking AI-driven oncology project. The initiative aims to enhance the process of bringing cancer therapies to market by utilizing OneMedNet's regulatory-grade patient data to develop external control arms (ECAs). This innovative approach promises a more efficient and cost-effective alternative to traditional clinical trials, potentially accelerating access to life-saving treatments. By leveraging real-world data, the project seeks to expedite regulatory and reimbursement approvals, particularly in areas with high unmet needs such as colorectal cancer. This collaboration marks a significant step forward in the use of real-world evidence for cancer therapeutics, aligning with the growing trend of employing data-driven methodologies to optimize clinical development.